New collaboration is clinic’s second in emerging personalized wellness field.
The biotechnology company officially kicked off its IPO on Wednesday.
Instead of prescribing an opioid-based treatment plan, the Intellis system offers doctors a non-opioid approach to treating chronic back pain.
The startup’s personalized medicine test offers a unique potential in Asia, where people take similar medications to Americans and Europeans but don’t share the same genetic makeup.
Manufactured ‘XNA’ can bind to proteins that regulate cardiac function.
U of M spinoff has tech to analyze microbial communities for health, ag clients.
The Plymouth-based company was testing a product used to treat dysfunctions in the Eustachian tube in the nose.
The company is developing treatments for gastrointestinal issues that use human gut bacteria.
If fundraising efforts (and an animal testing round) are successful, the founder of St. Jude Medical and Guidant said his latest startup will move forward to testing its artificial blood vessel on humans.